Last updated: Aug 26, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06024772 | 3 | Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | Unknown mechanism |
| NCT07164443 | 3 | A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Unknown mechanism |
| NCT06022822 | 2 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | Unknown mechanism |
| NCT06085664 | 1, 2 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | Prostate-specific membrane antigen (PSMA) + CD28 -- bispecific antibody |
| NCT07316686 | 1 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | Prostate-Specific Membrane Antigen (PSMA) -- targeted radioligand therapy with 177Lu-PSMA-I&T combined with docetaxel chemotherapy |
| Sponsor | Recruiting trials |
|---|---|
| University Health Network, Toronto | 21 |
| M.D. Anderson Cancer Center | 16 |
| Memorial Sloan Kettering Cancer Center | 15 |
| Mayo Clinic | 15 |
| National Cancer Institute (NCI) | 14 |
Countries/regions with the most active trial sites for prostate cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Mar 2028 | NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | Prostate-specific membrane antigen (PSMA) -- radioligand therapy with lutetium-177 labeled PSMA ligand |
| Nov 30, 2026 | NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | Prostate cancer antigens -- autologous cellular immunotherapy (Sipuleucel-T) + IL-15 superagonist -- immune activation (N-803) |
| Nov 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Regulatory T cells -- gene-edited cell therapy |
| Oct 2026 | NCT07674771 | Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery | PSMA -- radiolabeled ligand for PET imaging and targeted radiotherapy |
| Aug 31, 2026 | NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | Androgen receptor -- androgen receptor antagonists (enzalutamide, apalutamide, bicalutamide) and neurokinin 3 receptor -- small molecule antagonist (fezolinetant) |
| Aug 30, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | CXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor) |
| Aug 17, 2026 | NCT07746713 | A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer | PARP1/2 -- PARP inhibitor |
| Aug 10, 2026 | NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | PSCA -- chimeric antigen receptor T-cell therapy (CAR-T) |
You've seen the prostate cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.